Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 30 of the 40 sources its claims cite were checked for support.

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

Open access
Hundal, Jasmin, Veettil, Abhinav Anand Vayal, Chung, Caroline, Hosseini, Mohammad · 2026 · American Society of Clinical Oncology Educational Book

Abstract

Artificial intelligence (AI) is increasingly integrated into oncology across clinical care, research workflows, and translational implementation. This chapter provides a practical overview of these domains, emphasizing opportunities and limitations relevant to real-world oncology practice. In clinical care, AI applications include ambient documentation systems, decision support tools, and remote monitoring platforms. These technologies may reduce administrative burden, assist with evidence synthesis and guideline navigation, and enable longitudinal assessment of symptoms and functional status through wearable and patient-reported data. Emerging tools such as large language models also support patient communication through education, translation, and symptom triage. However, across these applications, performance remains dependent on data quality, validation, and appropriate clinical oversight. In research and scholarship, AI is increasingly used to support grant development, study design, literature review, and manuscript preparation. These tools may improve efficiency, enhance clarity, and assist in identifying research gaps or methodological approaches. At the same time, concerns regarding accuracy, hallucinated content, data privacy, and ethical responsibility require careful oversight. The responsibility for hypothesis generation, methodological rigor, and scientific integrity remains with the investigator. From a translational perspective, a persistent gap exists between model development and clinical deployment. Differences in data quality, infrastructure, and patient populations may limit generalizability, while workflow integration, clinician readiness, and bias mitigation remain critical challenges. Collectively, AI has the potential to enhance oncology care and research, but its impact depends on rigorous validation, equitable implementation, and sustained human oversight.

Overview

CoChat Summary

TL;DR

This ASCO Educational Book chapter provides a practical overview of AI in oncology across clinical care, research and scholarship, and translation, emphasizing opportunities and limitations for real-world practice. It argues that AI may improve workflow efficiency, evidence synthesis, monitoring, and patient communication, but its impact depends on rigorous validation, equitable implementation, and sustained human oversight.

Key findings

  • In clinical care, AI applications include ambient documentation, decision support, remote monitoring, wearables, and large language models for patient education, translation, and symptom triage; these may reduce administrative burden and enable earlier detection of treatment-related toxicities, with wearable monitoring demonstrating earlier detection of cytokine release syndrome in CAR T-cell therapy compared with standard clinical assessment.
  • In research and scholarship, generative AI may assist with grant development, study design, literature synthesis, manuscript preparation, and IRB applications, but risks include inaccuracy, hallucinated content, data privacy concerns, and ethical responsibility; in summer 2025, NIH grant review administrators reported receiving hundreds of proposals prepared with GenAI assistance, some containing fabricated or inaccurate references.
  • A persistent translational gap exists between model development and clinical deployment: curated academic datasets often differ from real-world data, leading to dataset shift, technical/infrastructural mismatches, data quality problems, demographic/clinical/biological differences, workflow integration challenges, and clinician readiness issues.
  • Responsible disclosure of AI use is framed as mandatory, optional, or unnecessary depending on whether use is intentional and substantial; mandatory examples include formulating questions or hypotheses, drafting or substantially revising text, translating, analyzing or interpreting data, extracting data for literature review, and generating synthetic data or images.

Methods

  • Design: narrative educational chapter/practical overview, not a primary study or systematic review.
  • Data or sample: no primary cohort or dataset is analyzed; the chapter draws on cited literature and examples across oncology AI.
  • Main analysis: thematic synthesis across clinical care, research and scholarship, and translation, including a table on disclosing AI use in research and writing adapted from Resnik and Hosseini 2025.

Limitations

  • The paper states that AI performance depends on data quality, validation, and clinical oversight; it also notes risks of hallucinations, bias, limited generalizability, workflow disruption, variable patient engagement, and heterogeneous or limited evidence for several applications.
  • Evident from the text: as a narrative overview, the chapter reports no systematic search strategy, inclusion criteria, formal quality appraisal, or primary data, so its conclusions are illustrative rather than systematically synthesized.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/edbk-26-517280

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

26 Valid · 3 Not valid · 7 Not checked · 38 Own results and interpretations

26 more claims · 11 with their cited sources checked

Create a free account to see all 74 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 28

Create a free account to see these claims.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Quinn R: NIH to Limit AI Use, Cap PI Grant Applications at 6 per Year. Insider Higher Ed. 2025. https://www.insidehighered.com/news/faculty-issues/research/2025/07/22/nih-limit-ai-use-cap-grant-applications-6-year

Cited by

See all 1

Metadata

Authors
Hundal, J., Veettil, A. A. V., Chung, C., & Hosseini, M.
Affiliations
  • Cleveland Clinic (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Northwestern University (US)
Venue
American Society of Clinical Oncology Educational Book
Published
2026-06
Volume
46
Issue
3
Pages
e517280-e517280
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W7164305352
Cited by
1
References
54
Citations by year
2026: 1
FWCI
1.95
Type
journal article
Language
en
Open access
Locations
  • American Society of Clinical Oncology Educational Book (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Physical Sciences › Computer Science › Artificial Intelligence › Artificial Intelligence Applications
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
Keywords
artificial intelligence in oncology, clinical decision support, remote patient monitoring, wearable devices, patient-reported outcomes, large language models, symptom triage, AI-assisted research, manuscript preparation, clinical implementation, model validation, generalizability, algorithmic bias, data privacy, human oversight, administrative burden
MeSH terms
Artificial Intelligence, Humans, Medical Oncology, Neoplasms, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation. https://app.cochat.ai/papers/10.1200/edbk-26-517280
The paper
Hundal, J., Veettil, A. A. V., Chung, C., & Hosseini, M. (2026). Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-26-517280

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.